On behalf of Magellan Rx Management, here is the quarterly communication document outlining the drug changes for the upcoming quarter beginning April 1.
Please note that going forward you will receive on a quarterly basis one Formulary document showing both the Magellan Rx Standard Formulary and the Magellan Rx Precision Formulary.
Product Update Background:
The Pharmacy and Therapeutics Committee (P&T), Therapeutic Assessment Committee (TAC), and Value Assessment Committee (VAC) meet periodically to review the status of each formulary and make recommendations. As a result of these periodic reviews, the Formulary may be modified. This update summarizes formulary and utilization management (edit) changes resulting from the committees’ most recent meetings.
Product Update Communications Plan:
If applicable, members with a prescription for any drug moving to Tier 3 status will receive a personalized letter naming the drug and identifying formulary therapeutic alternatives (Tier 1 & Tier 2) within two months of the effective date of this change.
Talking Points:
The Pharmacy and Therapeutics (P&T), Therapeutic Assessment Committee (TAC), and Value Assessment Committee (VAC) make changes to the formulary to help ensure that plan members have access to quality, safe and cost-effective prescription benefits.
If you have any questions regarding these changes, please feel free to contact your Account Manager or Sales Representative.
